John Leonard, AbbVie

John Leonard, AbbVie ($ABBV)
2012 Pay Package: $5.48 million
2011 Pay Package: $3.50 million
Percent change: +56.57%
2012 Compensation: $640,163 salary; $2.23 million in stock awards; $224,400 in option awards; $515,600 in incentive pay; $1.72 million in pension growth and deferred compensation; $149,142 in other compensation

Joining a slew of top R&D executives who have left their posts, John Leonard announced in May 2013 that he would bow out of the new Abbott Laboratories ($ABT) spinoff. Leonard started his Abbott career in 1992, became head of pharma R&D in 2012, and split off with AbbVie in January 2013.

As that spinoff neared, Abbott spent considerable time and money making deals for new R&D programs. So, when AbbVie ventured out on its own, it had a number of closely watched programs in its pockets, including several for hepatitis C, one of the hottest therapeutic areas out there. It is also heavily invested in antibody-drug conjugates, a new wave of cancer treatments.

In all, AbbVie hit the ground running with more than 20 mid- and late-stage therapies. But the newly minted pharma company has already posted some serious setbacks, including the failure of bardoxolone, a prospective treatment for chronic kidney disease that was linked with patient deaths.

For more:
AbbVie celebrates New Year's Day as a big new biopharma player
Humira stays strong for AbbVie as drugmaker scrambles for new offerings
AbbVie: We can beat Gilead in blockbuster hep C race
Pharma giant AbbVie backs biotech startup working on oral bowel drug
AbbVie's senior R&D exec Leonard joins exodus from the top ranks

-- Emily Mullin

John Leonard, AbbVie

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.